BioCentury | Sep 11, 2020
Product Development

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

...not having an honest debate in either camp...
BioCentury | Jul 29, 2020

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

With two RNA manipulation platforms united under one roof, Dutch biotech Vico will deploy its new series A round for clinical development of a program founder and Chairman Luc Dochez knows well from his time...
BioCentury | May 20, 2020
Tools & Techniques

Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs bar-coded transcriptional readouts of pathways activated downstream of G protein-coupled receptors (GPCRs), such as cAMP...
...Open COVID Pledge , and is supporting groups developing diagnostics based on the technology. Targets cAMP...
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease. Monday’s deal is Biogen’s second in...
BioCentury | Jan 11, 2020
Company News

Camp4’s platform to discover CNS targets in Biogen partnership

Following preclinical validation of its platform in liver indications, Camp4 has entered a collaboration with Biogen to apply its platform to CNS target discovery. Camp4 Therapeutics Corp. uses its Gene Circuitry Platform to build maps...
BioCentury | Dec 6, 2019
Politics & Policy

Revised Grassley, Wyden drug pricing bill more patient- and pharma-friendly

...that whatever happens this year, additional drug pricing legislation will be enacted in 2021. This camp...
BioCentury | Nov 8, 2019
Product Development

NIDA pushes for translational solutions to opioid crisis

One outcome of the flood of attention to the opioid crisis is that it is starting to sway the perception of addiction towards the concept it is a disease, suffered by patients, rather than a...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level. With a platform that homes in on the structural elements...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...have been deleted or suppressed, or delivering viral antigens conserved across many strains. The first camp...
Items per page:
1 - 10 of 314